The FDA has approved a new drug to help patients suffering from overactive bladder (OAB). Fesoterodine fumarate (Toviaz) works by relaxing the smooth muscle tissue of the bladder, thus reducing the urinary frequency, urge to urinate, and sudden urinary incontinence.